Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

104.54 -0.34 (-0.32%)
Official Closing Price Updated: 4:15 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
56 57 Next >
Defying the Norms: 3 High P/E Stocks With Room to Run
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations. 
Via InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This... 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa. 
Via Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,... 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Gilead Sciences
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab. 
Via Benzinga
Topics Death
Exposures Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
If you're looking for big income from blue-chip companies, these picks are for you. 
Via The Motley Fool
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
Looking for some safe higher-yielding dividend stocks today? These are seven of the best options in this volatile market. 
Via InvestorPlace
7 Dividend Stocks to Invest In for a Lifetime of Income
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment. 
Via InvestorPlace
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate... 
Via Benzinga
3 Dividend Stocks That Even Ken Griffin Is Buying
Billionaire investor Ken Griffin is filling the portfolio of his Citadel Advisors hedge fund with dividend paying stocks. 
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response... 
Via Benzinga
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.